What is the optimal management of renal failure in a patient with multiple myeloma?

Management of Renal Failure in Multiple Myeloma

Initiate bortezomib-based triplet chemotherapy immediately with high-dose dexamethasone in all patients with myeloma-related renal failure, as this is the gold standard that drives renal recovery through rapid reduction of nephrotoxic free light chains. 1, 2, 3

Immediate Diagnostic Workup

When renal failure is identified in a multiple myeloma patient, obtain the following laboratory studies without delay:

• Serum creatinine, estimated glomerular filtration rate (eGFR), and electrolytes 2, 3
• Serum free light chains (FLC) to quantify the nephrotoxic burden 2, 3
• 24-hour urine collection for total protein, electrophoresis, and immunofixation 2, 3
• Renal biopsy is indicated if non-selective proteinuria (mainly albuminuria) is present OR if involved serum FLC is <500 mg/L, as these findings suggest alternative renal pathology beyond cast nephropathy 2

First-Line Treatment: Bortezomib-Based Triplets

Bortezomib is uniquely suited for renal impairment because it is not renally cleared and is non-nephrotoxic, making it safe even in severe renal dysfunction including dialysis. 1

Preferred Regimen Options

Choose one of the following bortezomib-based triplets:

• Daratumumab + bortezomib + dexamethasone (D-Vd) 4, 2
• Bortezomib + lenalidomide + dexamethasone (VRd) with lenalidomide dose adjustment 4, 1, 2
• Bortezomib + cyclophosphamide + dexamethasone (VCd) 1, 5
• Bortezomib + doxorubicin + dexamethasone (PAD) 1, 6
• Bortezomib + thalidomide + dexamethasone (VTd) 1, 5

Evidence Supporting Bortezomib Triplets

The superiority of bortezomib-based triplets is demonstrated by the VISTA trial, where bortezomib-melphalan-prednisone achieved 37% renal recovery in patients with eGFR <30 mL/min/1.73 m², versus only 7% with melphalan-prednisone doublet therapy. 1 In patients receiving bortezomib-doxorubicin-dexamethasone with median baseline eGFR of 20.5 mL/min, the overall response rate was 72% with 52% achieving ≥VGPR. 1

Dexamethasone Dosing

Administer high-dose dexamethasone for at least the first month of therapy to maximize early free light chain reduction. 3

Lenalidomide Dose Adjustments for Renal Impairment

When using lenalidomide-containing regimens, adjust dosing based on creatinine clearance:

• CrCl >30 to ≤50 mL/min: 10 mg daily 1
• CrCl <30 mL/min (non-dialysis): 15 mg every 48 hours 1
• Dialysis-dependent: 5 mg daily after each dialysis session 1

Lenalidomide is effective and safe in mild to moderate renal impairment; in severe renal impairment or dialysis, monitor closely for hematologic toxicity. 3

Critical Agent to Avoid

Carfilzomib should be avoided in patients with acute kidney injury due to significant renal toxicity including thrombotic microangiopathy risk. 1 When carfilzomib has been used in this setting, overall response rates are modest (≈25%) with all responses limited to partial remission or less. 1 However, carfilzomib can be safely administered to patients with stable chronic kidney disease and creatinine clearance >15 mL/min. 3

Monitoring Treatment Response

Early Biomarker Targets

Achieving serum free light chain concentration <50 mg/dL at the end of cycle 1 predicts better renal recovery and serves as an early benchmark for treatment adequacy. 1 The magnitude of FLC reduction is more critical than exact timing; comparable renal outcomes occur whether the reduction is reached on day 12 versus day 21 of the first cycle. 1

Renal Response Criteria

Use the International Myeloma Working Group criteria for defining renal response. 2, 3 Monitor serum creatinine and eGFR regularly, as reversal of renal failure occurs in approximately 40% of patients with a median time to reversal of 17 days when using bortezomib-based regimens. 6

Correlation Between Hematologic and Renal Response

The depth of hematologic response directly correlates with renal recovery. 1 In patients receiving bortezomib-doxorubicin-dexamethasone:

• ≥VGPR: median post-treatment eGFR 59.6 mL/min 1
• Partial response: median post-treatment eGFR 38.9 mL/min 1
• Stable disease or less: median post-treatment eGFR 16.8 mL/min 1

This demonstrates that achieving ≥VGPR is the principal therapeutic goal for renal recovery. 1

Essential Supportive Care Measures

Implement the following supportive measures concurrently with chemotherapy:

• High fluid intake (adequate hydration) to reduce free light chain concentration and prevent tubular precipitation 2, 3
• Discontinue all nephrotoxic medications 1
• Correct hypercalcemia promptly if present 1
• Maintain euvolemia 1

Role of Dialysis

High-cutoff hemodialysis membranes combined with chemotherapy may improve renal function recovery and can be considered as an adjunct to antimyeloma therapy. 3 However, mechanical approaches alone do not increase overall survival. 2

Standard high-flux or high-cutoff membranes can be used during hemodialysis in combination with chemotherapy. 7

Autologous Stem Cell Transplantation

High-dose melphalan (100-140 mg/m²) with autologous stem cell transplantation is feasible in patients with renal impairment who are otherwise eligible candidates. 3, 8 ASCT is effective and tolerated in patients with moderate renal impairment. 9

Relapsed/Refractory Disease with Renal Impairment

For patients with relapsed/refractory disease and renal impairment, newer treatment options are available:

• Quadruplet and triplet combinations including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies improve both renal and survival outcomes 2
• CAR-T cell therapy and bispecific antibodies are effective and tolerated in patients with moderate renal impairment 9, 8
• Pomalidomide is an option in bortezomib-refractory patients 5
• Ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with CrCl >30 mL/min 3

Common Pitfalls to Avoid

• Do not delay initiation of chemotherapy while awaiting renal biopsy results in patients with clear myeloma cast nephropathy (high FLC burden with selective light chain proteinuria); start bortezomib-dexamethasone immediately 1
• Do not use carfilzomib in acute kidney injury due to nephrotoxicity risk 1
• Do not underdose lenalidomide without proper adjustment; follow the specific dose modifications for renal function 1
• Do not use thalidomide without dose adjustment concerns; thalidomide requires no dose modification for renal impairment and is effective 3, 5